# Pliant Therapeutics

**Source:** https://geo.sig.ai/brands/pliant-therapeutics  
**Vertical:** BioTech  
**Subcategory:** Fibrotic Disease  
**Tier:** Challenger  
**Website:** pliantrx.com  
**Last Updated:** 2026-04-14

## Summary

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

## Company Overview

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Pliant's lead asset bexotegrast (PLN-74809) is a dual αvβ6/αvβ1 inhibitor advancing in Phase 2b/3 trials for IPF — a fatal lung scarring disease with median survival of 3–5 years after diagnosis. IPF affects 100,000+ U.S. patients with two approved therapies that only slow progression. Bexotegrast's Phase 2 data showed lung function stabilization and biomarker improvements that have sustained investor and partner interest.

Listed on Nasdaq since 2019, Pliant has established itself as the leading pure-play integrin inhibitor company for fibrosis. The company's pipeline extends to liver fibrosis (PSC, MASH) and kidney fibrosis, targeting markets where no approved anti-fibrotic therapies exist and where integrin biology is well-validated by genetics and preclinical models.

## Frequently Asked Questions

### What is Pliant Therapeutics developing?
Pliant develops small molecule integrin inhibitors for fibrotic diseases, with lead drug bexotegrast targeting IPF (lung scarring) in Phase 2b/3 trials and pipeline programs for liver and kidney fibrosis.

### How do integrin inhibitors fight fibrosis?
Integrins activate TGF-β, the master driver of tissue scarring. Blocking specific integrin subtypes (αvβ6, αvβ1) prevents TGF-β activation, halting the fibrotic cascade without broadly suppressing immunity.

### What is the IPF market opportunity?
IPF affects 100,000+ U.S. patients with only two approved therapies that slow (not stop) progression. A therapy that stabilizes or reverses lung function decline would address a multi-billion dollar unmet need.

### What is Pliant Therapeutics' lead clinical program?
Pliant's lead program is bexotegrast (PLN-74809), a dual αvβ6/αvβ1 integrin inhibitor in Phase 2 trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Interim Phase 2 data in IPF showed lung function stabilization at 24 weeks — functional decline reversal — in a disease where current standard-of-care only slows decline. Pliant is a publicly traded company (Nasdaq: PLRX) with market cap reflecting the IPF clinical program's potential.

### Why are αvβ6 and αvβ1 integrins important in fibrosis?
αvβ6 and αvβ1 integrins activate TGF-β — the master fibrotic cytokine — by releasing it from its latent form in the extracellular matrix. Blocking these integrins prevents TGF-β activation, reducing fibroblast differentiation into collagen-secreting myofibroblasts. The integrin approach is upstream of existing anti-fibrotic mechanisms (nintedanib inhibits growth factor receptors downstream of TGF-β; pirfenidone has poorly understood anti-fibrotic effects) — potentially offering complementary or superior efficacy.

### What is the IPF market and competitive landscape?
IPF affects approximately 130,000 patients in the US with median survival of 3-5 years from diagnosis. Current therapies (nintedanib, pirfenidone) slow progression by ~50% but do not arrest disease. The IPF drug market exceeds $3 billion annually and supports premium pricing — new therapies demonstrating superior efficacy to existing standard-of-care can command $50,000-100,000+ annually per patient. Pliant competes with FibroGen (pamrevlumab failed Phase 3), Bellerophon Therapeutics, and Roche's inhaled approach.

### What is Pliant's PSC program and why is PSC important?
Primary sclerosing cholangitis (PSC) is a rare, progressive liver and bile duct disease with no approved treatments and median time to liver transplant or death of 13-17 years from diagnosis. Bexotegrast's αvβ1 component targets biliary fibrosis, the dominant pathological mechanism in PSC. PSC's orphan disease status enables FDA fast track and breakthrough designations, smaller clinical trials, and premium pricing — an attractive regulatory and commercial profile that complements the larger IPF opportunity.

### What is Pliant's financial position and runway?
As a public company (Nasdaq: PLRX), Pliant has accessed capital markets to fund its clinical programs, with cash runway supporting ongoing Phase 2 trials and Phase 3 planning for bexotegrast in IPF and PSC. The company has filed for Fast Track Designation for key programs and actively explores partnership opportunities with larger pharmaceutical companies who may seek to co-develop or acquire bexotegrast given the validated IPF clinical data.

## Tags

healthtech, technology, public, b2b, startup

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*